FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295254711> ?p ?o ?g. }

• W4295254711 abstract "<h3>Background</h3> Children with Down Syndrome (DS) are at increased risk of coeliac disease (CD). Current screening practice in DS includes tissue transglutaminase IgA (TGA-IgA) serology. There is no standard UK guidance on frequency of serology testing or inclusion of HLA-typing for CD predisposing antigens, DQ2 and DQ8. HLA testing can be performed before gluten exposure and to coincide with other routine investigations. A negative DQ2/DQ8 type means patients do not require further coeliac screening. A positive DQ2/DQ8 type allows risk stratification of patients. We explored the cost-effectiveness and family acceptance of a screening strategy which involved both serology and HLA-typing of children with DS. <h3>Methods</h3> Children in Lothian with DS were screened for coeliac disease using HLA-DQ2/DQ8 typing and IgA-TGA serology as part of an established programme following publication of 2012/2013 guidelines from ESPGHAN/BSPGHAN, seen as ‘standard of care’. Data collected included the frequency of HLA DQ2/DQ8, assessed with serology testing. Existing patients with CD were identified as part of analysis of the Lothian DS cohort. The cost of HLA haplotyping in NHS Lothian is £31.16, TGA-IgA £15.92 and Total IgA £3.66. <h3>Results</h3> 127 of 176 children with DS (73%) were screened using DQ typing. One family did not consent to DQ typing or serology. Overall, DQ2/DQ8 antigens were identified in 75 (59%) and 52 (41%) were negative . Patients with known CD who were tested (9 out of 12) were all DQ2/DQ8 positive. TGA-IgA serology was performed in 143 of 176 (82%) with a median number of tests per patient of 1. Compared to only TGA-IgA screening, there was an estimated saving of £3.37 per patient. <h3>Conclusions</h3> A significant minority (41%) of DS children are negative for CD-predisposing HLA genotypes and are therefore excluded from further screening. DQ typing is a cost-effective CD screening strategy and was generally well received. In addition to the modest saving in laboratory costs, there will be further benefits from reduction in frequency of serology screening: reduced hidden costs within phlebotomy, diminished pressure on health services, and savings to families of both expense and time. A negative DQ type also excludes a significant condition for families dealing with other complex health issues, the benefit of which cannot be underestimated. The Down Syndrome Medical Interest Group in the UK are considering the adoption of such a strategy." @default.
• W4295254711 created "2022-09-12" @default.
• W4295254711 creator A5001611271 @default.
• W4295254711 creator A5011602004 @default.
• W4295254711 creator A5028293460 @default.
• W4295254711 creator A5044154106 @default.
• W4295254711 creator A5049709547 @default.
• W4295254711 creator A5051536895 @default.
• W4295254711 creator A5051549321 @default.
• W4295254711 creator A5082049761 @default.
• W4295254711 date "2022-04-01" @default.
• W4295254711 modified "2023-09-27" @default.
• W4295254711 title "O4 HLA-typing as a cost effective screening test for coeliac disease in children with down syndrome" @default.
• W4295254711 doi "https://doi.org/10.1136/flgastro-2022-bspghan.4" @default.
• W4295254711 hasPublicationYear "2022" @default.
• W4295254711 type Work @default.
• W4295254711 citedByCount "0" @default.
• W4295254711 crossrefType "proceedings-article" @default.
• W4295254711 hasAuthorship W4295254711A5001611271 @default.
• W4295254711 hasAuthorship W4295254711A5011602004 @default.
• W4295254711 hasAuthorship W4295254711A5028293460 @default.
• W4295254711 hasAuthorship W4295254711A5044154106 @default.
• W4295254711 hasAuthorship W4295254711A5049709547 @default.
• W4295254711 hasAuthorship W4295254711A5051536895 @default.
• W4295254711 hasAuthorship W4295254711A5051549321 @default.
• W4295254711 hasAuthorship W4295254711A5082049761 @default.
• W4295254711 hasConcept C126322002 @default.
• W4295254711 hasConcept C147483822 @default.
• W4295254711 hasConcept C159654299 @default.
• W4295254711 hasConcept C188280979 @default.
• W4295254711 hasConcept C203014093 @default.
• W4295254711 hasConcept C2779134260 @default.
• W4295254711 hasConcept C2780349322 @default.
• W4295254711 hasConcept C2781209916 @default.
• W4295254711 hasConcept C45189115 @default.
• W4295254711 hasConcept C54355233 @default.
• W4295254711 hasConcept C71924100 @default.
• W4295254711 hasConcept C86803240 @default.
• W4295254711 hasConceptScore W4295254711C126322002 @default.
• W4295254711 hasConceptScore W4295254711C147483822 @default.
• W4295254711 hasConceptScore W4295254711C159654299 @default.
• W4295254711 hasConceptScore W4295254711C188280979 @default.
• W4295254711 hasConceptScore W4295254711C203014093 @default.
• W4295254711 hasConceptScore W4295254711C2779134260 @default.
• W4295254711 hasConceptScore W4295254711C2780349322 @default.
• W4295254711 hasConceptScore W4295254711C2781209916 @default.
• W4295254711 hasConceptScore W4295254711C45189115 @default.
• W4295254711 hasConceptScore W4295254711C54355233 @default.
• W4295254711 hasConceptScore W4295254711C71924100 @default.
• W4295254711 hasConceptScore W4295254711C86803240 @default.
• W4295254711 hasLocation W42952547111 @default.
• W4295254711 hasOpenAccess W4295254711 @default.
• W4295254711 hasPrimaryLocation W42952547111 @default.
• W4295254711 hasRelatedWork W123302256 @default.
• W4295254711 hasRelatedWork W1996382806 @default.
• W4295254711 hasRelatedWork W2069132109 @default.
• W4295254711 hasRelatedWork W2088011034 @default.
• W4295254711 hasRelatedWork W2386787114 @default.
• W4295254711 hasRelatedWork W2389942666 @default.
• W4295254711 hasRelatedWork W2398525239 @default.
• W4295254711 hasRelatedWork W2415141377 @default.
• W4295254711 hasRelatedWork W2539843858 @default.
• W4295254711 hasRelatedWork W3143543034 @default.
• W4295254711 isParatext "false" @default.
• W4295254711 isRetracted "false" @default.
• W4295254711 workType "article" @default.